Public disclosures

Kumar Neil

Company insiders · Chief Executive Officer · Director · BridgeBio Pharma, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-20.Following & alerts
Reported transaction lines
15
Buy lines
0
Sell lines
6

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-1115

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 475686 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $79.04 to $79.73 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

2026-11-192026-11-20

≈ $118,939.50

1,500 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 477186 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $78.00 to $78.98 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

2026-11-192026-11-20

≈ $665,977.55

8,500 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 485686 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

2026-11-182026-11-20

≈ $678,884.05

8,723 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Indirect ownership · By Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. · Reported balance after transaction: 494409 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. · The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

2026-11-182026-11-20

≈ $98,318.15

1,277 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 243327 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $77.43 to $78.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

2026-11-182026-11-20

≈ $2,372,948.28

30,490 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 273817 · SEC code covers open-market or private transactions · This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on May 13, 2026. · Represents the weighted average sale price of the shares sold from $76.43 to $77.42 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

2026-11-182026-11-20

≈ $345,692.28

4,490 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 84755 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2026. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

2026-11-162026-11-18

6,519 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 103984 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2025. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

2026-11-162026-11-18

11,554 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 97997 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2024. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

2026-11-162026-11-18

19,599 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Restricted Stock Units · Derivative security · Direct ownership · Reported balance after transaction: 33544 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. · The RSUs vested with respect to 1/16th of the underlying shares on May 16, 2023. Thereafter, 1/16th of the underlying shares vest on a quarterly basis, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.

2026-11-162026-11-18

33,544 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Other transaction
Filing details

SEC transaction code F

Common Stock · Direct ownership · Reported balance after transaction: 278307 · Securities delivered or withheld for tax or exercise payment · Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 71,216 shares of Common Stock underlying the Reporting Person's RSUs.

2026-11-162026-11-18

36,236 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 314543 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2026-11-162026-11-18

6,519 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 308024 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2026-11-162026-11-18

11,554 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 296470 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2026-11-162026-11-18

19,599 shares/units

SEC 4
Kumar Neil

Chief Executive Officer · Director · BridgeBio Pharma, Inc.

BBIO

BridgeBio Pharma, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 276871 · Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2026-11-162026-11-18

33,544 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement